PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Berry Consultants LLC, Austin, Texas, United States of America.\', \'M.D. Anderson Cancer Center of the University of Texas, Houston, Texas, United States of America.\', \'Division of Outcomes and Value Research, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.\', \'John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.\', \'Hackensack Meridian Health School of Medicine, Nutley, New Jersey, United States of America.\', \'Hackensack Meridian Health, Edison, New Jersey, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1371/journal.pone.0255228
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 34329317
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
is ?:relation_isRelatedTo_publication of
?:title
  • Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all